vacc-4x
Vaccineexperimental
Clinical trial activity
5 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2008 (NCT00659789)
Timeline
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vacc-4x
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02092116 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | Aarhus University, Bionor Pharma, Celgene |
| NCT01712256 | Phase 2 | Dec 1, 2012 | Bionor Pharma |
| NCT01704781 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2012 | Bionor Pharma, Celgene |
| NCT01473810 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2011 | Bionor Pharma, Eurocine Vaccines AB, Osaka University |
| NCT00659789 | Phase 2 | Aug 1, 2008 | Bionor Pharma, University of California, Davis |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bionor Pharma | For profit | 5 | 4 | 1 | 2008 |
| Celgene | For profit | 2 | 0 | 1 | 2012 |
| Aarhus University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Eurocine Vaccines AB | For profit | 1 | 0 | 1 | 2011 |
| Osaka University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| University of California, Davis | Academic/Hospital | 1 | 0 | 1 | 2008 |
6 organizations
Page 1 / 1